Results 211 to 220 of about 79,407 (254)

Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women

Science, 2017
Nichole R Klatt, Kenzie Birse, Alexander S Zevin   +2 more
exaly   +2 more sources

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Journal of Hepatology, 2018
Kosh Agarwal, Young-Suk Lim, Scott Fung
exaly   +2 more sources

Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia

Liver international (Print), 2021
About 20% of patients receiving nucleos(t)ide analogues treatment experienced low‐level viraemia (LLV), which is associated with progression of liver fibrosis and high risk of hepatocellular carcinoma. We aimed to evaluate the effectiveness and safety of
Zhong-Bin Li, Le Li, Xiaoxia Niu, Song-hai Chen, Yi-ming Fu, Chun-Yan Wang, Yan Liu, Q. Shao, Guo-feng Chen, D. Ji   +9 more
semanticscholar   +1 more source

Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV

Current Opinion in HIV and AIDS, 2021
Purpose of review Obesity is increasing in people with HIV (PWH). This review aims to summarise the recent evidence investigating the associations between the use of integrase inhibitors and tenofovir alafenamide (TAF) with weight gain and the mechanisms
J. Lake, J. Trevillyan
semanticscholar   +1 more source

Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection

Hepatology, 2020
Studies have suggested that tenofovir disoproxil fumarate (TDF) treatment is associated with a significantly lower risk of hepatocellular carcinoma (HCC) occurrence when compared with entecavir (ETV) therapy in patients with chronic hepatitis B. We aimed
Jonggi Choi, Chanyoung Jo, Y. Lim
semanticscholar   +1 more source

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

Hepatology, 2017
George Papatheodoridis, Ramazan Idilman, George N Dalekos   +2 more
exaly   +2 more sources

Tenofovir is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.

Gastroenterology, 2019
BACKGROUND & AIMS There have been conflicting results from studies comparing the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection treated with tenofovir disoproxil fumarate (TDF) vs those treated with ...
Terry Cheuk-Fung Yip, V. Wai‐Sun Wong, Henry Lik-Yuen Chan, Y. Tse, Grace Chung-Yan Lui, Grace Lai-Hung Wong   +5 more
semanticscholar   +1 more source

Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice

Hepatology, 2021
Real‐world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) are limited.
H. Toyoda, J. Leong, C. Landis, M. Atsukawa, Tsunamasa Watanabe, Daniel Q. Huang, J. Liu, S. Quek, T. Ishikawa, T. Arai, Keisuke Yokohama, M. Chuma, K. Takaguchi, H. Uojima, Tomonori Senoo, H. Dang, Mayumi Maeda, J. Hoang, R. Le, S. Yasuda, K. Thin, S. Tran, Nicholas Chien, L. Henry, A. Asai, S. Fukunishi, R. Cheung, S. Lim, H. Trinh, M. Nguyen   +29 more
semanticscholar   +1 more source

Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B

Liver international (Print), 2020
Tenofovir alafenamide (TAF) has been newly approved for the treatment of chronic hepatitis B (CHB). We aimed to assess the effectiveness and renal safety of switching from entecavir (ETV) or nucleos(t)ide analogue (NA) combination therapy to TAF.
E. Ogawa, H. Nomura, M. Nakamuta, N. Furusyo, Toshimasa Koyanagi, K. Dohmen, Aritsune Ooho, T. Satoh, A. Kawano, E. Kajiwara, Kazuhiro Takahashi, K. Azuma, Masaki Kato, S. Shimoda, J. Hayashi   +14 more
semanticscholar   +1 more source

Tenofovir

Reactions Weekly, 2011
  +6 more sources